Search

Displaying results 2951 - 2960 of 4301 in total
  1. Drug

    Rocuronium

    go.drugbank.com/drugs/DB00728
    ApprovedInvestigational

    Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotra...

  2. Drug

    Pexelizumab

    go.drugbank.com/drugs/DB04949
    Investigational

    It is being investigated by Alexion Pharmaceuticals.

  3. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  4. Drug

    Velusetrag

    go.drugbank.com/drugs/DB12702
    Investigational

    It is being developed by Theravance. … Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research program dedicated to finding new treatments for GI motility disorders.

  5. Drug

    E59

    go.drugbank.com/drugs/DB18372
    Experimental

    It was developed by Sixal Inc.

  6. Drug

    JNJ-17216498

    go.drugbank.com/drugs/DB17087
    Investigational

    JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.[A253997]

  7. Drug

    BB-1701

    go.drugbank.com/drugs/DB17443
    Investigational

    BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.

  8. Drug

    Adelmidrol

    go.drugbank.com/drugs/DB16083
    Investigational

    Placebo for Gynecologic Oncology Patients Affected by Vaginitis).

  9. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  10. Drug

    TBC-3711

    go.drugbank.com/drugs/DB05407
    Investigational

    TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.